Bristol-Myers
Squibb Company BMY and Five
Prime Therapeutics, Inc. FPRX today announced that they
have entered into an exclusive worldwide license and collaboration
agreement for the development and commercialization of Five Prime's
colony stimulating factor 1 receptor (CSF1R) antibody program, including
FPA008 which is in Phase 1 development for immunology and oncology
indications. This agreement replaces the companies' existing clinical
collaboration agreement to evaluate the safety, tolerability and
preliminary efficacy of combining Opdivo (nivolumab),
Bristol-Myers Squibb's programmed-death 1 (PD-1) immune checkpoint
inhibitor, with FPA008 in six tumor types.
"By blocking a key mediator of immunosuppression in the tumor
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in